A Study of Intravenous Perampanel in Japanese Participants With Epilepsy

NCT03754582 | Completed Phase 2 Results

• 1 other identifier: E2007-J081-240
• Study Type: interventional
• Target: 21
• Locations: 1 country
• Sites: 13

Brief Summary

The purpose of the study is to evaluate the safety and tolerability of perampanel administered as a 30-minute intravenous infusion after switching from oral tablets (8 to 12 milligrams per day \[mg/day\]) as an adjunctive therapy in participants with epilepsy with partial onset seizures (POS) (including secondarily generalized seizures) or primary generalized tonic-clonic (PGTC) seizures.

Conditions

Epilepsy; Seizures

Keywords

Partial Onset Seizures; Secondarily Generalized Seizures; Primary Generalized Tonic-Clonic Seizures

Outcome Measures

Primary Outcomes (6)

• Number of Participants With Serious Adverse Events (SAEs)

  A SAE was defined as any untoward medical occurrence that at any dose: Resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect.

  Up to 60 days (Pretreatment Phase: up to 28 days, Treatment Phase: up to 4 days, Follow-up Phase: up to 28 days after last dose)

• Number of Participants With Adverse Events (AEs)

  An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the investigational product, any new disease or exacerbation of an existing disease, any deterioration in nonprotocol-required measurements of a laboratory value or other clinical test that resulted in symptoms, a change in treatment, or discontinuation of study drug, recurrence of an intermittent medical condition not present pretreatment, an abnormal laboratory test result was considered an AE if the identified laboratory abnormality led to any type of intervention, withdrawal of study drug, or withholding of study drug, whether prescribed in the protocol or not.

  Up to 60 days (Pretreatment Phase: up to 28 days, Treatment Phase: up to 4 days, Follow-up Phase: up to 28 days after last dose)

• Number of Participants With Markedly Abnormal Clinical Laboratory Parameter Values During Treatment and Follow-up Phase

  Up to Day 11 (Treatment Phase: at Day 4, Follow-up Phase: up to 7 days after last dose)

• Number of Participants With Abnormal Vital Sign Values During Treatment and Follow-up Phase

  Up to 11 days (Treatment Phase: up to 4 days, Follow-up Phase: up to 7 days after the last dose)

• Number of Participants With Abnormal Body Weight During Treatment and Follow-up Phase

  Up to 11 days (Treatment Phase: up to 4 days, Follow-up Phase: up to 7 days after the last dose)

• Number of Participants With Clinically Significant Markedly Abnormal Electrocardiogram (ECG) Value During Treatment and Follow-up Phase

  Up to Day 11 (Treatment Phase: at Day 4, Follow-up Phase: up to 7 days after the last dose)

Secondary Outcomes (2)

• Mean Seizure Frequency Per Day in Pretreatment Phase, Treatment Phase and Follow-up Phase

  Up to 39 days (Pretreatment Phase: up to 28 days; Treatment Phase: up to 4 days; Follow-up Phase: up to 7 days after the last dose)

• Plasma Concentration of Perampanel Before and After Switching From Oral Perampanel to 30-minute Intravenous Infusions of Perampanel

  Pretreatment Phase-Day -1: Pre-dose, 0.5 hours, 1 hours and 1.5 hours post-dose; Treatment Phase-Day 1, Day 2, Day 3 and Day 4: Pre-dose and 0.5 hours after start of intravenous infusions

Study Arms (1)

Perampanel

EXPERIMENTAL

Participants with POS with or without secondarily generalized seizures or PGTC seizures will receive perampanel 8 to 12 milligram (mg), tablets, orally, once daily for 28 days (Day -28 to Day -1) in Pretreatment Phase and followed by 8 to 12 mg dose of perampanel as intravenous infusion for 30 minutes, once daily from Day 1 to Day 4 in Treatment Phase, and then again 8 to 12 mg, tablets, orally, once daily from Day 5 to Day 11 in Follow-up Phase as an adjunctive therapy, along with 1 to a maximum of 3 marketed concomitant antiepileptic drugs (AEDs).

Drug: Perampanel

Interventions

Perampanel DRUG

Oral tablets.

Also known as: E2007

Perampanel

Eligibility Criteria

• Age: 12 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• A diagnosis of epilepsy with POS (including secondarily generalized seizures) or PGTC seizures according to the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures (1981).
• Receiving a stable dose regimen of oral perampanel.
• Receiving a concomitant stable dose regimen of marketed AEDs. No change of dosing regimen for concomitant AEDs is planned during the intravenous Treatment and Follow-up Phases.
• Considered reliable and willing to be available for the study period by the investigator, and are able to record seizures and report AEs by themselves or have a caregiver who can record seizures and report AEs for them.

You may not qualify if:

• A history of drug or alcohol dependency or abuse.
• A history of status epilepticus.
• Unsuitable for venipuncture and intravenous administration.
• Requires medical intervention due to safety issues related to concomitant administration of AEDs.
• A history of suicidal ideation/attempt.
• Clinical symptoms or imaging suggest progressive central nervous system (CNS) abnormality, disorder, or brain tumor.
• Current evidence of clinically significant disease (example, cardiac, respiratory, gastrointestinal, renal disease) that in the opinion of the investigators could affect the participant's safety, interfere with the study assessments or need prohibited medications as specified in the study protocol.
• Clinically significant abnormal laboratory values.
• Females of childbearing potential who:
• In the Pretreatment Phase, are breastfeeding or pregnant (as documented by a positive beta-human chorionic gonadotropin \[β-hCG\] test).
• Within 28 days before Visit 1, did not use a highly effective method of contraception, which includes any of the following:
• total abstinence (if it is their preferred and usual lifestyle).
• an intrauterine device (IUD) or intrauterine hormone-releasing system (IUS).
• a contraceptive implant.
• an oral contraceptive (with additional barrier method). (Participant must be on a stable dose of the same oral contraceptive product for at least 28 days before Day 1 of the Treatment Phase and throughout the entire study period, and for 28 days after the last dose of study drug).

Sponsors & Collaborators

• Eisai Co., Ltd.: lead

Study Sites (13)

Eisai trial site 5

Kurume, Fukuoka, Japan

Location

Eisai trial site 12

Sapporo, Hokkaido, Japan

Location

Eisai trial site 9

Ōmura, Nagasaki, Japan

Location

Eisai trial site 7

Sayama, Osaka, Japan

Location

Eisai trial site 2

Asaka, Saitama, Japan

Location

Eisai trial site 13

Hamamatsu, Shizuoka, Japan

Location

Eisai trial site 8

Kodaira, Tokyo, Japan

Location

Eisai trial site 10

Hiroshima, Japan

Location

Eisai trial site 6

Kagoshima, Japan

Location

Eisai trial site 1

Niigata, Japan

Location

Eisai trial site 11

Okayama, Japan

Location

Eisai trial site 3

Shizuoka, Japan

Location

Eisai trial site 4

Yamagata, Japan

Location

MeSH Terms

Conditions

Epilepsy; Seizures

Interventions

perampanel

Condition Hierarchy (Ancestors)

Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Results Point of Contact

• Title: Eisai Medical Information
• Organization: Eisai Co., Ltd.

esi_medinfo@eisai.com

+1-888-274-2378

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 15, 2018
• First Posted: November 27, 2018
• Study Start: November 27, 2018
• Primary Completion: December 10, 2019
• Study Completion: December 10, 2019
• Last Updated: January 5, 2021
• Results First Posted: January 5, 2021

Record last verified: 2019-11

Data Sharing

• IPD Sharing: Will share

Locations

JP (13)